Mitochondrial Atpif1 regulates heme synthesis in developing erythroblasts

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.1038/nature11536</td>
</tr>
<tr>
<td>Citable link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:11179038">http://nrs.harvard.edu/urn-3:HUL.InstRepos:11179038</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>
Mitochondrial Atpif1 regulates heme synthesis in developing erythroblasts

Dhvanit I. Shah1, Naoko Takahashi-Makise2, Jeffrey D. Cooney1,†, Liangtao Li2, Iman J. Schultz1,†, Eric L. Pierce1, Anupama Narla1,3, Alexandra Seguin2, Shilpa M. Hattangadi3,4, Amy E. Medlock5, Nathaniel B. Langer1,†, Tamara A. Dailey5, Slater N. Hurst1, Danilo Faccenda6, Jessica M. Wiwczar7,†, Spencer K. Heggers1, Guillaume Vogin1,†, Wen Chen1,†, Caiyong Chen1, Dean R. Campagna6, Carlo Brugnara9, Yi Zhou3, Benjamin L. Ebert1, Nika N. Danial7, Mark D. Fleming8, Diane M. Ward2, Michelangelo Campanella6, Harry A. Dailey5,†, Jerry Kaplan2,*, and Barry H. Paw1,3,†

1Department of Medicine, Division of Hematology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
2Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah 84312, USA
3Department of Medicine, Division of Hematology-Oncology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
4Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA
5Biomedical and Health Sciences Institute, Departments of Microbiology, Biochemistry & Molecular Biology, University of Georgia, Athens, Georgia 30602, USA
6Royal Veterinary College, University of London and University College London Consortium for Mitochondrial Research, London, NW1 0TU, UK
7Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA


Author Information The authors declare no competing financial interests
SUMMARY

Defects in the availability of heme substrates or the catalytic activity of the terminal enzyme in heme biosynthesis, ferrochelatase (Fech), impair heme synthesis, and thus cause human congenital anemias. The inter-dependent functions of regulators of mitochondrial homeostasis and enzymes responsible for heme synthesis are largely unknown. To uncover this unmet need, we utilized zebrafish genetic screens and cloned mitochondrial ATPase inhibitory factor 1 (atpif1) from a zebrafish mutant with profound anemia, pinotage (pnt<sup>209</sup>). We now report a direct mechanism establishing that Atpif1 regulates the catalytic efficiency of vertebrate Fech to synthesize heme. The loss of Atpif1 impairs hemoglobin synthesis in zebrafish, mouse, and human hematopoietic models as a consequence of diminished Fech activity, and elevated mitochondrial pH. To understand the relationship among mitochondrial pH, redox potential, [2Fe-2S] clusters, and Fech activity, we used (1) genetic complementation studies of Fech constructs with or without [2Fe-2S] clusters in pnt, and (2) pharmacological agents modulating mitochondrial pH and redox potential. The presence of [2Fe-2S] cluster renders vertebrate Fech vulnerable to Atpif1-regulated mitochondrial pH and redox potential perturbations. Therefore, Atpif1 deficiency reduces the efficiency of vertebrate Fech to synthesize heme, resulting in anemia. The novel mechanism of Atpif1 as a regulator of heme synthesis advances the understanding of mitochondrial heme homeostasis and red blood cell development. A deficiency of Atpif1 may contribute to important human diseases, such as congenital sideroblastic anemias and mitochondriopathies.

A deficiency in heme, which is used in a wide variety of metabolic and regulatory pathways in cells, results in pathological conditions that range from mild anemia to early in utero death. As an essential component of hemoglobin, the individual enzymes and substrates of heme biosynthesis have been well studied; however, key gaps remain in our knowledge of genes that regulate iron and heme trafficking and homeostasis. This incomplete understanding prevents researchers from developing targeted therapies for a broad range of disorders, including congenital anemias and porphyrias, as well as metabolic and neurological disorders.

We recovered pnt, a zebrafish non-lethal recessive mutant, from an unbiased ethyl nitrosourea (ENU) mutagenesis screen for defects in circulating erythroid cells. pnt embryos were anemic (Fig. 1a) despite normal expression of erythroid cell markers, β-globin and band-3 (data not shown). Based on red cell indices, the erythrocytes from pnt embryos that survive to adult stage exhibited hypochromic, microcytic anemia (Supplementary Fig. 1a). Histological analysis of adult pnt hematopoietic tissues, showed no gross morphological defects (Supplementary Fig. 1b).

The positional cloning and chromosomal walk identified the most telomeric gene, the mitochondrial ATPase inhibitory factor 1 (atpif1a; zgc:162207), as the most likely candidate for the pnt locus (Fig. 1b). Phylogenetic analysis showed that an ATPase inhibitory factor 1-like protein (atpif1b; zgc: 153321) on Chr. 17 is 71% similar to atpif1a at the amino acid level (Fig. 1d), and is likely the result of gene duplication in teleosts. Peptide alignments further displayed human (ATPIF1, chromosome 1) and mouse (Atpif1, chromosome 4) homologs for atpif1a and atpif1b (Fig. 1c). Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) showed reduced levels of atpif1a mRNA in pnt embryos (Fig. 1d) and pnt adult kidney marrow compared to respective wild-type (WT) controls.
(Supplementary Fig. 1c). The levels of atpif1b mRNA were, however, unchanged in pnt embryos (Fig. 1d) and elevated 2 to 3-fold in pnt adult kidney marrow (Supplementary Fig. 1c). Thus, atpif1a is likely the gene disrupted in the pnt locus. Previous studies have shown that mitochondrial Atpif1 regulates the proton motive force via mitochondrial influx of H⁺ ions, mitochondrial structure, and ATP synthesis, indicating that Atpif1 is required in a wide range of metabolically active tissues. The broad requirement for Atpif1 is reinforced by the ubiquitous expression of both atpif1a and atpif1b in zebrafish embryos (Supplementary Fig. 1d), and Atpif1 in various mouse adult and fetal organs (Supplementary Fig. 1e).

To verify the loss-of-function phenotype for atpif1a, we injected two atpif1a antisense morpholinos (MO), a splice-blocking (Fig. 2a) and a translational-blocking (data not shown), to knock down atpif1a expression in zebrafish embryos. The atpif1a-silenced embryos (morphants) lacked hemoglobinized cells, as detected by o-dianisidine staining, thereby phenocopying the anemia in pnt embryos (Fig. 2a). The anemic phenotype in the morphant embryos correlates with a reduction of atpif1a mRNA levels, verifying that the splice-blocking MO accurately targeted atpif1a (Fig. 2b, Supplementary Discussion 1, Supplementary Figs. 2a–2d).

To further validate that atpif1a is the gene disrupted in pnt, we over-expressed atpif1a cRNA in pnt embryos and subsequently evaluated their hemoglobinization. To assess the specificity of our complementation assay, we also injected pnt embryos with non-functional atpif1a cRNA harboring a mis-sense mutation (E26A) in the regulatory inhibitory domain. Only functional atpif1a complemented the anemia in pnt embryos (Fig. 2c), thereby confirming that atpif1a is the gene disrupted in pnt embryos. Consistent with 2 to 3-fold increase in atpif1b expression in surviving pnt adults (Supplementary Fig. 1c), the ectopic-expression of atpif1b cRNA also complemented pnt anemia (Fig. 2c), a result of their redundant function. These data suggest that the hypomorphic and viable phenotype of pnt could be attributed to the ability of atpif1b to partially compensate for the loss of function of atpif1a (Supplementary Fig. 1c). This is in contrast to other situations with paralogous genes such as the mitoferrin (mfrn) transporters.

To identify a genetic mutation in the pnt locus, we first sequenced the open reading frame (ORF) and splice junctions of the atpif1a gene and found no mutation. Instead, a polymorphism in the 3′ untranslated region (UTR) of the atpif1a gene was discovered (Fig. 2d). This mutation was linked to the pnt locus following the distinct segregation of WT and mutant (MT) conformations on single-strand conformational polymorphism (SSCP) (Fig. 2e). To establish the functional consequences of the 3′ UTR polymorphism on the stability of atpif1a mRNA, we designed constructs containing the zebrafish atpif1a ORF fused with either the WT or polymorphic 3′ UTR sequences, and transfected mouse erythroleukemia (MEL) cells with each construct individually for stable selection (Supplementary Fig. 2e). qRT-PCR analysis showed a decrease in steady state atpif1a mRNA levels in cells harboring polymorphic 3′ UTR constructs as compared to the WT construct (Fig. 2f, Supplementary Discussion 2). These data functionally demonstrate that the polymorphism in the 3′ UTR of the atpif1a gene destabilizes its steady state mRNA. The observed decrease in the atpif1a mRNA level in pnt embryos (Fig. 1d) is consistent with the ascribed function for the 3′ UTR polymorphism, which destabilizes atpif1a steady state mRNA and leads to its degradation.

In mammalian cells, Atpf1 is located in the inner mitochondrial membrane and primarily regulates the function of the F1F0-ATP synthase. There is, however, no direct evidence suggesting a role for Atpf1 in heme synthesis or erythropoiesis. To ascertain the role of Atpif1 in mammalian heme synthesis, we utilized short hairpin RNAs (shRNAs) to stably silence Atpif1 in differentiating mammalian erythroid cells: human primary CD34+
(hCD34+) cells, mouse primary fetal liver (MPFL), and MEL cells. The reduced number of
hemoglobinized cells in Atpif1-silenced hCD34+ and MEL cells (Fig. 3a, Supplementary
Fig. 3a) and the reduced hemoglobin content in MPFL cells transduced with Atpif1-shRNAs
(Supplementary Figs. 3b–3c), demonstrate conserved heme-specific function of Atpif1.
Consistent with a high turnover of heme in developing erythroblasts, we observed that the
hemoglobinization defect was specific to Atpif1-silenced differentiating erythroid cells.
Similarly, we observed that the expression of Atpif1 protein increases along with other
proteins required for heme synthesis, such as Fech and mitoferrin1 (Mfrn1, Slc25a37),
during terminal erythroid maturation (Supplementary Fig. 3d). Analogous Atpif1-silencing
experiments performed in non-erythroid (NIH3T3) and undifferentiated MEL cells showed
no measurable heme defects (Supplementary Fig. 4). This indicates that Atpif1 is essential
for terminal erythroid maturation and is not critical for heme synthesis in non-erythroid
cells and early erythroid progenitors.

Under physiological conditions, the F1F0-ATP synthase generates a proton motive force and
ATP by transporting H+ ions into the mitochondria. Under oxidative stress, the F1F0-
ATP synthase reverses the direction of H+ transport, thus reducing ATP and proton motive
force. Atpif1 inhibits the reversal of F1F0-ATP synthase to reduce ATP hydrolysis,
thereby maintaining the mitochondrial membrane potential and proton motive force. To
determine the causal association between the roles of Atpif1 in mitochondrial homeostasis
and mammalian heme synthesis, we used stable Atpif1-shRNA-silenced MEL cells.
Consistent with the silencing of Atpif1, the Atpif1 protein levels were reduced (Fig. 3b).
While excluding the possibility of global mitochondrial structural dysfunction: (1) We found
normal protein expression of integral mitochondrial proteins, such as the β-subunit of ATP
synthase (AtpB), complex IV (Cox IV), voltage-dependent anionic-selective channel protein
1 (Vdac1), and heat shock protein 60 (Hsp60) (Fig. 3b). (2) Electron microscopic and
biochemical analysis revealed normal integrity of the mitochondria; indicating that the gross
structural architecture of mitochondria in Atpif1-silenced MEL cells was preserved (Fig. 3b,
Supplementary Fig. 5). We, however, found that the loss of Atpif1 in differentiating MEL
cells caused a depletion of cellular ATP levels (Supplementary Figs. 6a–6b), an increase
in mitochondrial membrane potential (ΔΨm) (Fig. 3c, Supplementary Fig. 6c), and an
alkalinization of the mitochondria (Supplementary Fig. 6d).

Heme synthesis requires the incorporation of ferrous ion (Fe²⁺) into protoporphyrin IX
(PPIX), which is catalyzed by Fech on the matrix side of the inner mitochondrial
membrane. Since the loss of Atpif1 results primarily in a defect of heme synthesis in
differentiating erythroid cells, we analyzed the mitochondrial levels of heme substrates,
heme, and their enzymes. We have previously shown that Mfrn1, an inner mitochondrial
membrane transporter, facilitates the import of Fe into erythroid mitochondria; which is
dependent upon the mitochondrial ΔΨm. Consistent with the increased mitochondrial
ΔΨm in Atpif1-silenced MEL cells (Fig. 3c, Supplementary Fig. 6c), the uptake of radio-
labeled iron (⁵⁹Fe) into the mitochondria was increased (Fig. 3d), indicating that the loss of
Atpif1 increases mitochondrial iron load. Iron transported into the mitochondrial matrix is
either: 1) utilized to make [2Fe-2S] clusters, or 2) incorporated into PPIX by Fech to
generate heme. Atpif1-silenced MEL cells had normal levels of mitochondrial PPIX
(Fig. 3e), suggesting that enzymes and substrates necessary to make this heme precursor are
not rate-limiting. The incorporation of ⁵⁹Fe into PPIX to generate heme, however, was
reduced (Fig. 3f), despite having sufficient levels of Fech substrates, iron and PPIX. We
predicted that the catalytic efficiency of Fech might have been compromised, and thus, we
measured the protein expression levels of Fech and Fech activity. Although normal levels of
Fech protein were present, Fech activity was reduced (Fig. 4a), suggesting that the defect in
heme synthesis in pnt could be attributed to a reduction in Fech activity. We found that the
basal mitochondrial pH of control cells was pH 7.4, and for Atpif1-silenced MEL cells was
pH 8.6 (Fig. 4b, Supplementary Fig. 6d). Since \textit{Atpif1}-silenced MEL cells have higher basal mitochondrial pH, we predicted that (1) elevated mitochondrial pH might influence the efficiency of Fech to make heme, and (2) the Fech isolated from these cells is already harmfully influenced by the elevated pH. To experimentally support our hypothesis, we pre-incubated the purified human Fech at pH 7.4, 8.0, 8.5, and 9.0 for 1 hr, and then run Fech assay at pH 7.4. We found that pre-incubation at elevated pH have harmful impact on human Fech, and thus reduces its capacity to make heme (Supplementary Fig. 6e). In addition, we found that increasing mitochondrial pH to 8.5 and pH 9.0 would further lower Fech activity in both control and \textit{Atpif1}-silenced MEL cells (Fig. 4c), indicating the Fech activity is a function of mitochondrial pH (Supplementary Discussion 3). Altogether, these data suggest that the ability of Fech to generate heme was compromised due to the increase in mitochondrial pH that occurs in \textit{Atpif1}-silenced differentiating MEL cells.

We further found that the lowering mitochondrial membrane potential and thus mitochondrial pH, using pharmacological agents carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP; 1 mM; 1hr) and 2, 4-dinitro-phenol (2,4-DNP; 500 \(\mu\)M; 1hr), could rescue anemic phenotype in \textit{Atpif1}-silenced MEL cells (Fig. 4d). These data reinforce our observation that \textit{Atpif1} regulates heme synthesis via its modulation of the mitochondrial \(\Psi_m\) and mitochondrial pH.

\textit{Atpif1}-silenced MEL cells have normal cytosolic and mitochondrial [2Fe-2S] cluster biogenesis as they have normal activities of proteins dependent on [2Fe-2S] cluster synthesis, such as cytosolic xanthine oxidase (Supplementary Fig. 7a), and mitochondrial aconitase (Fig. 4e). The post-translational stability of Fech apoprotein depends on iron availability and an intact [2Fe-2S] cluster assembly machinery\(^{20,21}\). However, the functional role of the [2Fe-2S] cluster in Fech activity remains unknown (Supplementary Discussion 4). All vertebrate Fech enzymes possess [2Fe-2S] clusters, whereas Fech from the yeast \textit{Saccharomyces cerevisiae} does not have a cluster\(^{16,21}\). Based on these data and our current observations, we hypothesized that the [2Fe-2S] cluster of Fech could influence Fech activity \textit{in situ} by rendering Fech responsive to changes in the mitochondrial proton motive force, and thus mitochondrial pH and redox potential.

To experimentally test whether [2Fe-2S] cluster-bound Fech responded to the capacity of \textit{Atpif1} to regulate mitochondrial proton motive force and thus mitochondrial pH, we designed constructs containing either zebrafish Fech (with [2Fe-2S]) or yeast Fech (without [2Fe-2S]) with the vertebrate mitochondrial targeting pro-peptide for cRNA injections. Both constructs, irrespective of the presence of [2Fe-2S] clusters, functionally complemented a genetic deficiency for zebrafish Fech in \textit{freixenet}\(^{6,22}\) (\textit{tx}u271, Supplementary Fig. 7b). When either zebrafish Fech or yeast Fech cRNA was injected into \textit{pnt} embryos, the yeast Fech rescued \textit{pnt} anemia, while zebrafish Fech did not (Fig. 4f). These data suggest that it is the [2Fe-2S] cluster of the zebrafish Fech that makes this enzyme vulnerable to pH perturbations of the mitochondrial matrix in \textit{atpif1}-deficient \textit{pnt} embryos. Therefore, \textit{Atpif1} plays an essential role in stabilizing the activity of [2Fe-2S] cluster-containing Fech by modulating changes in mitochondrial matrix pH. Based upon our results, we infer that yeast Fech, lacking the [2Fe-2S] cluster, is resistant to mitochondrial pH changes in \textit{pnt} embryos. Consistent with our observation that the activity of yeast Fech would be unaffected by mitochondrial pH (Fig. 4f), we found that the deficiency of \textit{Inh1} did not produce a defect in heme synthesis (data not shown). These data show that \textit{Atpif1} regulates heme synthesis in higher vertebrate erythroid tissues, while its counterpart in baker’s yeast, \textit{Inh1}, does not regulate heme synthesis.

The redox potential of mitochondrial matrix at pH 7.4 is -280 mV, and it is reduced to -370 mV at pH 8.4\(^{23}\). Since the mitochondrial pH is inversely related to mitochondrial redox
potential, we further analyzed the susceptibility of the [2Fe-2S] of Fech to reduction in mitochondrial redox potential. When we treated human Fech (with [2Fe-2S]) and yeast Fech (without [2Fe-2S]) with a strong reducing agent, sodium dithionate (DTN, 10 mM), we found that the DTN treatment could only reduce the activity of human Fech and not the activity of yeast Fech (Fig. 4g). This further suggests that [2Fe-2S] of vertebrate Fech is sensitive to the reduction in the redox potential. Thus, the Fech activity is reduced in Atpifl-silenced MEL cells as its [2Fe-2S] cluster is sensitive to an elevation of pH (Fig. 4b, 4c, 4d, 4f) and a reduction in redox potential (Fig. 4g), and not due to a defect in [2Fe-2S] cluster biosynthetic assembly (Fig. 4e, Supplementary Fig. 7a).

To exclude an anemic phenotype in pnt as a causal effect of reactive oxygen species (ROS) induced heme degradation, we treated pnt mutant embryos with N-acetyl cysteine (NAC, 10 μM, 48 hr), a potent antioxidant employed for ROS studies in zebrafish embryos, and found that NAC could not rescue pnt anemia (Fig. 4h). This demonstrates that anemic phenotype in pnt is not due to increased ROS generation. The heme-oxygenase-1 enzyme (Hmox1) is a ROS-responsive, cellular enzyme responsible for heme degradation. We found normal transcript levels of Hmox1 in control and Atpifl-silenced MEL cells (Supplementary Fig. 7c). Consistent with our model, it has been demonstrated that 1) only overexpression of Atpifl, not loss of Atpifl activity, induces ROS production, independent of the Hif1α pathway, and 2) the overexpression of Atpifl did not affect cellular hydrogen peroxide levels, indicating that the Atpifl-mediated superoxide signal is of mild-intensity and localized in mitochondria. Altogether, these data suggest that ROS and heme degradation are not responsible for the heme defect we observed in erythroid cells.

In summary, Atpifl modulates the mitochondrial pH and redox potential, and thus allows Fech to efficiently catalyze the incorporation of iron into PPIX to produce heme. Loss of Atpifl allows the mitochondrial pH and, consequently, the redox potential to change to a level that reduces [2Fe-2S] cluster-containing Fech activity, thereby reducing heme synthesis, resulting in hypochromic anemia in pnt (Fig. 4i). Previous human studies have identified ALAS2, FXN, ABCB7, and SLC25A38 as the genetic causes of congenital sideroblastic anemias. Data presented herein demonstrate that Atpifl should now be added to the list of proteins whose native function is required for normal erythropoiesis. This makes Atpifl a candidate gene for the understanding and treatment of human sideroblastic anemias and mitochondrial disorders.

METHODS SUMMARY

All procedures were approved by the Animal Care and Use Committee of Boston Children’s Hospital. We performed complete blood count and Wright-Geimsa analyses on peripheral blood recovered from adult pnt. Genetic mapping and positional cloning were utilized to identify zgc: 162207 (atpifla) as the candidate gene for the pnt locus on zebrafish Chr. 19. We employed qRT-PCR using TaqMan gene expression assays (Applied Biosystems, Carlsbad, CA) to measure levels of atpifla and atpiflb mRNA. Morpholinos (Gene Tools, Philomath, OR) against splice-site of atpifla and atpiflb were designed and injected in WT embryos to verify loss-of-function phenotype. The cRNA for atpifla, atpifla-E26A, and atpiflb were injected in pnt embryos for complementation. The cDNA prepared from WT and pnt embryos was sequenced, and the polymorphism in the 3’UTR of the atpifla sequence was verified using SSCP gels.

We silenced Atpifl in hCD34+, MPFL and MEL using shRNAs. The Atpifl-silenced, differentiated hCD34+ and MEL cells were stained with o-dianisidine to measure hemoglobinized cells, while MPFL cells were treated with Drabkin’s reagent to measure relative hemoglobin content. The loss of Atpifl protein and the state of mitochondrial
structural proteins in MEL cells were verified using western and electron microscopic analyses. We analyzed fluorescent intensities of TMRE as a function of mitochondrial membrane potential, Mg green as a function of ATP levels, and ratio of carboxy SNARF-1 to Mitotracker green as a function of the mitochondrial matrix pH8, 12.

We prepared 59Fe-saturated transferrin, and measured 59Fe incorporated in mitochondria and complexed in heme using a gamma counter. We examined PPIX levels and the catalytic efficiency of Fech in MEL cells using spectrophotometric analysis. The MEL cells were treated with FCCP and 2,4-DNP, followed by analysis for hemoglobinized cells. Human and yeast Fech were treated with DTN, and subsequently their catalytic efficiency were measured. Aconitase activity was determined as a measure of [2Fe-2S] cluster levels29. The cRNA for zebrafish Fech or yeast Fech was injected in pnt embryos, and their efficiency to rescue the anemia in pnt was measured using o-dianisidine staining and verified by using SSCP analysis10. Statistical analyses were performed by paired or un-paired t-test. Significance was set at p<0.05.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank members of our lab (Michelle Cassim, Adam Kaplan, Gordon Hildick-Smith, and Heidi Anderson) and colleagues (Seth L. Alper, Karen Pepper, and Nikoiaus S. Trede) for critical review of the manuscript, Terrence C. Law for pnt adult blood characterization, Howard Mulhern for help with the electron microscopy, Christopher Lawrence and his team for the zebrafish husbandry. This research was supported in part by the Cooley’s Anemia Foundation (D.I.S., C.C.), the March of Dimes Foundation (B.H.P.), the American Heart Association (J.D.C., A.E.M.), the Dutch National Science Fund (I.J.S.), the Fondation Soldati pour la Recherche en Cancerologie (G.V.), the Burroughs Welcome Fund (N.N.D.), the NIDDK (D.I.S., B.H.P., A.N., J.K., H.A.D., S.M.H.), and the NHLBI (D.I.S., B.H.P).

References


Fig. 1. Disruption of atpif1 in pinotage (pnt^tq209) produces hypochromic anemia

a, pnt embryos are severely anemic. Wild-type (WT) embryo at 72 hpf exhibits o-dianisidine stained (brown) hemoglobinized cells. b, The positional cloning of the pnt locus on zebrafish chromosome (Chr.) 19. A positional cloning effort with 1,912 diploid pnt embryos identified the closest linked genetic marker, z42828b. We initiated a chromosomal walk, at a distance of ~0.01 centimorgan (cM) from the pnt locus. The BAC clone, encompassing the pnt locus, is shown below, along with the annotated genes within the critical physical contig.

c, Phylogenetic dendrogram showing the amino acid homology between the various atpif1 genes. D. rerio (Dr) atpif1a aligns with its related paralog, atpif1b, on zebrafish Chr. 17. Both atpif1a and atpif1b are shown clustering with their functional mammalian orthologs from mouse (Mm) and human (Hs).

d, qRT-PCR analysis of atpif1a and atpif1b mRNA in pnt and WT embryos, showing reduced atpif1a and normal atpif1b mRNA level in pnt.
*p<0.05 (t-test, n=3)
**Fig. 2. Functional characterization of the atpif1a gene**

a, Splice blocking morpholino (MO) knock down of *atpif1a* phenocopies the anemia observed in *pnt* embryos. b, qRT-PCR analysis shows that the anemic phenotype is due to the accurate knockdown of *atpif1a*. c, Ectopic expression of *atpif1a* or *atpif1b* cRNA functionally complements the anemia in *pnt* embryos at 72 hpf. WT control, *pnt*, and rescued *pnt* embryos complemented with *atpif1a* or *atpif1b* cRNA are stained with *o*-dianisidine. The non-functional *atpif1a*, harboring the E26A mutation, specifically failed to complement the *pnt* anemia. d, *pnt* embryos have an AC polymorphism in the 3′ UTR of the *atpif1a* gene. e, The 3′ UTR AC polymorphism co-segregates with the *pnt* phenotype by SSCP analysis. The SSCP segregation pattern for lanes 1–2 (+/+), lane 3 (+/*pnt*), and lanes 4–6 (*pnt*/*pnt*). f, The mutant AC polymorphism in the 3′ UTR of the *atpif1a* cDNA functionally destabilizes its mRNA. MT construct stably expressed in MEL cells showed reduced *atpif1a* mRNA levels. *p<0.05 (t-test, n=3)
Fig. 3. Loss of Atpif1 produces a hemoglobinization defect in mammalian cells

a, Silencing of Atpif1 in human CD34+ (left) and MEL (right) cells with shRNAs (Human: H1\textsuperscript{sh} & H2\textsuperscript{sh}, Mouse: M1\textsuperscript{sh}) results in a hemoglobinization defect. 
b, Western analysis in Atpif1-shRNA (Mouse: M1\textsuperscript{sh}) silenced MEL cells. Atpif1 protein level is reduced in Atpif1-shRNA (M1\textsuperscript{sh})-silenced cells. However, the mitochondrial structural proteins, AtpB, CoxIV, Vdac1, and Hsp60, are not affected.
c, Silencing of Atpif1 elevates the mitochondrial membrane potential ($\Delta\Psi_m$), analyzed using a TMRE fluorescence probe in the presence of verapamil and FCCP.
d, Silencing of Atpif1 elevates the import of $^{59}$Fe in the mitochondria, consistent with the increased mitochondrial $\Delta\Psi_m$.
e, Silencing of Atpif1 does not influence the formation of protoporphyrin IX (PPIX), indicating PPIX and iron are not limited for heme synthesis.
f, The level of $^{59}$Fe incorporated in heme is greatly reduced in Atpif1-silenced MEL cells, recapitulating the heme synthesis defect in pnt. *p<0.05 (t-test, n=3)
Fig. 4. Atpif1 regulates heme synthesis by modulating Fech activity

a, Ferrochelatase (Fech) protein levels are normal (top right); however, the Fech activity is reduced in Atpif1-silenced MEL cells. b, Silencing of Atpif1 increases the mitochondrial matrix pH to 8.6. The histogram summarizes values at resting conditions and after challenge with oligomycin that normalizes the initial difference. c, Analysis of Fech activity as a function of pH. The elevation of mitochondria pH to 8.5 & 9.0 markedly reduced the Fech activity. d, Drugs lowering mitochondrial membrane potential reverses the anemic phenotype due to loss of Atpif1. Treatment of FCCP and 2, 4-DNP complements the anemic phenotype of Atpif1-silenced MEL cells. e, Aconitase activity, a marker for mitochondrial [2Fe-2S] cluster synthesis, is normal in Atpif1-silenced MEL cells. f, The presence of [2Fe-2S] cluster makes Fech susceptible to mitochondrial pH alteration in the absence of Atpif1. Yeast Fech, lacking [2Fe-2S], complements put anemia, indicating a resistance to pH changes in the absence of atpif1. Zebrafish Fech, containing [2Fe-2S], does not complement put anemia, indicating its susceptibility to mitochondrial alkalinization. g, The [2Fe-2S] of Fech is sensitive to the reduction in redox potential. The treatment of DTN reduces human Fech activity, and does not affect yeast Fech activity. h, Reactive oxygen species (ROS) are not responsible for put anemia. Treatment of put embryos with N-acetyl cysteine (NAC) does not reverse put anemia. i, A proposed mechanistic model of Atpif1 function in the maintenance of mitochondrial pH and regulation of Fech activity for heme synthesis. Mitochondrial heme synthesis requires Fech to incorporate iron into PPIX at physiological pH. Atpif1 normally preserves the mitochondrial pH. Loss of Atpif1 alkalinizes mitochondrial pH, the presence of [2Fe-2S] cluster makes Fech susceptible to mitochondrial pH and redox potential perturbations, and consequently reduces its catalytic efficiency for the production of heme. *p<0.05 (t-test, n=3); ‡p<0.05 vs. control cells at pH 8.5 (t-test, n=3)

Nature. Author manuscript; available in PMC 2013 May 22.